Table 2 Type of surgery and tumour characteristics.

From: Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials

 

Anastrozole n (%)

Fulvestrant n (%)

Surgery

  

  Breast-conserving surgery

67 (60.4)

56 (52.8)

  Radical mastectomy

44 (39.6)

44 (41.5)

  None

–

6 (5.7)

pT

  

 pT1/T2

100 (90.1)

77 (72.6)

 pT3/T4

9 (8.1)

16 (15.1)

 NA

2 (1.8)

13 (12.3)

pN

  

 Negative

54 (48.6)

42 (39.6)

 Positive

55 (49.6)

53 (50)

 NA

2 (1.8)

11 (10.4)

Pathological responsea

  

  Non-responder

86 (77.5)

80 (75.5)

  Responder

20 (18.0)

14 (13.2)

  NA

5 (4.5)

12 (11.3)

Allred ER score

  

  0–5

1 (0.9)

18 (16.9)

  6–8

102 (91.9)

72 (67.9)

  NA

8 (7.2)

16 (15.2)

Ki-67

  

  ≤10%

72 (64.9)

65 (61.3)

  >10%

22 (19.8)

21 (19.8)

  NA

17 (15.3)

20 (18.9)

PEPI group

  

  I and II (<4)

56 (50.5)

48 (45.3)

  III (≥4)

36 (32.4)

30 (28.3)

  NA

19 (17.1)

28 (26.4)

  1. TA combined with NA or NB and TB with NA or NB indicate an objective pathological response.
  2. NA not available, PEPI preoperative endocrine prognostic index.
  3. aaccording to the Sataloff classification.13
  4. NA not available, PEPI preoperative endocrine prognostic index.
Back to article page